• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Past Event

An EQ-5D-5L Value Set for England

OHE Lunchtime Seminar with Professor Nancy Devlin, Office of Health Economics and Professor Ben van Hout, University of Sheffield OHE Lunchtime Seminar with Professor Nancy Devlin, Office of Health Economics and Professor Ben van Hout, University of Sheffield   An…

Date

30/10/14 12:00 am

OHE Lunchtime Seminar with Professor Nancy Devlin, Office of Health Economics and Professor Ben van Hout, University of Sheffield

OHE Lunchtime Seminar with Professor Nancy Devlin, Office of Health Economics and Professor Ben van Hout, University of Sheffield
 
An EQ-5D-5L value set for England
 
Thursday 30 October 2014, 12:00-2:00pm.
 
The EQ-5D is a generic preference-based instrument that is widely used to measure and value changes in health-related quality of life. Respondents self-report their health in terms of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) with three response levels in each (no, some or extreme problems). A new version of the instrument (EQ-5D-5L) with five response levels (no, slight, moderate, severe or extreme problems) is now available.  Increasing the number of levels increases the ability of the EQ-5D-5L to capture impacts on and improvements in health that may have been missed by the EQ-5D-3L. 
 
New algorithms are needed to link EQ-5D-5L health state descriptions to utility values for use in calculating quality-adjusted life years. The aim of this project was both to explore theoretical issues relating to how best to elicit and model preferences, and to produce an EQ-5D-5L value set for England. 
 
Professor Nancy Devlin at the Office of Health Economics and Professor Ben van Hout of the University of Sheffield were awarded a research grant from the Policy Research Programme (PRP) of the UK’s National Institute for Health Research (NIHR) for this research (‘An EQ-5D-5L Value Set for England’ – 070/0073). The project team for this research also includes Koonal Shah and Yan Feng from OHE and Brendan Mulhern from the University of Sheffield.
 
Members of the general public in England (n=996), selected at random from residential post codes, were interviewed by professional interviewers from Ipsos MORI during the period of November 2012 and March 2013 using a protocol developed by the EuroQol Group. Each respondent was asked to value 10 health states using a composite Time Trade Off (TTO) approach, and seven paired comparisons of health states via Discrete Choice Experiment (DCE) tasks. Extensive work was undertaken in modelling the data in alternative ways. The final model selected for the EQ-5D-5L value set for England was a 20 parameter hybrid model (i.e. using both TTO and DCE data) with censored errors/opinions. 
 
In this seminar, the new EQ-5D-5L value set will be presented, and the methods used to obtain and model the data explained. The characteristics of the new value set will be compared with those of the UK value set currently in use for EQ-5D, and with the interim value set for the EQ-5D-5L produced by a cross walk to the EQ-5D-3L. Policy and research implications will be discussed. 
 

Related Events

Tekado
  • Past Event
  • Commissioned Webinar
  • August 2023

Partnerships for Health System Innovation and Improvement

Read more
Eco-conscious car journeying through forest landscape, Earth pla
  • Past Event
  • Annual Lecture
  • July 2023

OHE Annual Lecture 2023 | The ECO-nomics of Health in a Shifting Climate: Fostering Well-being, Sustainable Livelihoods, and a Greener Future

Read more
cape-town-2575437
  • Past Event
  • July 2023

OHE at IHEA 2023

Read more
sustainaibiity
  • Past Event
  • OHE Webinar
  • Sponsored Webinar
  • May 2023

Supporting Sustainability in the Era of Green Pharmaceuticals

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!